• Clinical Insights — January Issue 2

    Welcome to the second January edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Formulation Approval Humulin® R KwikPen® (insulin human injection) – New Formulation Approval January 21, 2016 – The U.S. Food and Drug Administration approved Eli Lilly and Company’s Humulin®… Read more »

  • Clinical Insights — January Issue 1

    Welcome to the first January edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.     New Drug Approval Zurampic® (lesinurad) December 22, 2015 – The U.S. Food and Drug Administration approved Zurampic® (lesinurad) to treat high levels of uric acid in the blood… Read more »

  • December 340B Insider

    Welcome to the December edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   Highlights from ASHP Midyear Clinical Meeting This month, the RxStrategies’ team was pleased to participate in ASHP’s Midyear Clinical Meeting and Exhibition, one of the largest gatherings of pharmacists in the world. A Few… Read more »

  • RxStrategies Clinical Insights — November 2015, Issue 2

    Welcome to the second November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.     New Drug Approval Ninlaro® (ixazomib) November 20, 2015 – The U.S. Food and Drug Administration approved ixazomib (Ninlaro®, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical… Read more »

  • RxStrategies Clinical Insights — November Issue 1

    Welcome to the first November edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Imlygic™ (talimogene laherparepvec) October 27, 2015 — The U.S. Food and Drug Administration approved Imlygic™ (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the… Read more »

  • RxStrategies, Inc. Names Skip Devanny Chief Revenue Officer

    BOCA RATON, Fla., October 28, 2015—RxStrategies, Inc. (www.rxstrategies.com) is pleased to announce the appointment of Skip Devanny to the position of Chief Revenue Officer. In this new role, Skip joins the RxStrategies’ senior leadership team and has responsibility for sales and marketing including the delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace. “I… Read more »

  • RxStrategies Connects with Industry Leaders from Coast to Coast

    It has been a pleasure for the RxStrategies team to connect with industry leaders during events across the country this month. Last week, we traveled to Jekyll Island, Georgia, for the Georgia Association for Primary Health Care (GAPHC) 2015 Annual Conference, and to Sacramento, California, for the California Primary Care Association (CPCA) Annual Conference. To learn more about… Read more »

    Last week, we traveled to Jekyll Island, Georgia, for the Georgia Association for Primary Health Care (GAPHC) 2015 Annual Conference, and to Sacramento, California, for the California Primary Care Association (CPCA) Annual Conference.

    To learn more about our 340B solutions, and how to position your organization for success with the 340B Drug Pricing Program, call us at 877-GoGetRx.

     

    -->